Guillon, Antoine
Jouan, Youenn
Kassa-Sombo, Arthur
Paget, Christophe
Dequin, Pierre-François
Article History
Received: 15 March 2024
Accepted: 22 March 2024
First Online: 28 March 2024
Declarations
:
: The ImPACT study (Clinical Trial.gov identifier: NCT03379207) was approved by the ethics committee (Comité de Protection de Personnes Ile-de- France 8). The CAPE COVID trial (ClinicalTrials.gov Identifier: NCT02517489) was approved by the ethics committee (Comité de Protection des Personnes Ouest 1, France). Each patient or surrogate provided either written or oral informed consent prior to inclusion.
: Pr Dequin reported receiving grants from Aerogen and Fisher & Paykel Healthcare and personal fees from Aridis Pharmaceuticals. No other authors reported disclosures.